Kenvue Inc. (KVUE) Average EV/EBITDA Ratio
The current ev/ebitda ratio for Kenvue Inc. (KVUE) is 13.56x as of Wednesday, June 24, 2026, shown against its trailing averages.
KVUE Average EV/EBITDA Ratio Chart
KVUE EV/EBITDA Ratio Averages
EV/EBITDA RATIO CURRENT
13.56x
EV/EBITDA RATIO TTM
14.57x
EV/EBITDA RATIO 3Y
16.28x
EV/EBITDA RATIO 5Y
16.25x
EV/EBITDA RATIO 10Y
16.25x
EV/EBITDA RATIO 15Y
16.25x
EV/EBITDA RATIO 20Y
16.25x
About Kenvue Inc.
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- CEO
- Kirk L. Perry